Replies to post #4323 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Changing the protein sequence NXS to NXT, could in theory produce an immune response, independently of glycosylation patterns. But the chances of this are low, IMHO.<

OK, we’re on the same wavelength: changes in the amino acid sequence are a theoretical concern only—there is no evidence whatsoever that this would ever occur in GTC’s production platform.